1800 103 7100
info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

Amgen heart failure drug deal is good news — but little more — for Cytokinetics – San Francisco Business Times (blog)

July 9, 2013Organ Failureadmin

Amgen heart failure drug deal is good news — but little more — for Cytokinetics
San Francisco Business Times (blog)
Thousand Oaks-based Amgen, meanwhile, received U.S. commercial rights to Servier's chronic heart failure drug ivabradine, which is approved in Europe, and an exclusive option to develop and commercialize Servier's Phase II heart failure drug S-38844 in ...

and more »

Post navigation

← Surrey man turns to India for transplant donor after years waiting in BC (w … – Vancouver Desi Dying friend inspired David Harewood – Zee News →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Powered by WordPress , Theme i-excel by TemplatesNext.
MENU
    • About
    • Free Downloads
    • Videos